Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients

Clinical and Experimental Immunology

Volumn 119, Issue 1, 2000, Pages 28-37

  Haicheur, N ^a   Escudier, B ^a,b   Dorval, T ^a   Negrier, S ^a,c   De Mulder, P H M ^a,d   Dupuy, J M ^a,e   Novick, D ^a,f   Guilloth, T ^a,e   Wolf, S ^a,g   Pouillart, P ^a   Fridman, W H ^a   Tartour, E ^a  

^a INSTITUT CURIE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE LÉON BÉRARD   (France)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Wyeth Lederle   (France)

^f WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^g Genetics Institute Cambridge   (United States)

Author keywords

Cancer; Cytokine; IL 12; Immunotherapy; Soluble cytokine receptor

Indexed keywords

BETA ACTIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; RECOMBINANT INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG TOXICITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MONONUCLEAR CELL; PERIPHERAL CIRCULATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN INDUCTION; RECEPTOR UPREGULATION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CHEMOKINES; CHEMOKINES, CXC; CYTOKINES; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CYTOKINE; RECEPTORS, INTERLEUKIN-4; RECOMBINANT PROTEINS; RNA, MESSENGER; SOLUBILITY; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033973093     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01112.x     Document Type: Article

References (62)

1. 1 Kobayashi M, Fitz L, Ryan M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170:827-45.
2. 2 Stern AS, Podlaski FJ, Hulmes JD et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 1990; 87:6808-12.
3. 3 Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70:83-243.
4. 4 Manetti R, Parronchi P, Giudizi MG et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177:1199-204.
5. + T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260:547-9.
6. 6 Magram J, Connaughton SE, Warrier RR et al. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 1996; 4:471-81.
7. 7 Rogge L, Barberis-Maino L, Biffi M et al. Selective expression of an interleukin-12 receptor component by human T helper I cells. J Exp Med 1997; 185:825-31.
8. 8 Gately MK, Renzetti LM, Magram J et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998; 16:495-521.
9. 9 Brunda MJ, Luistro L, Warrier RR et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178:1223-30.
10. 10 Vagliani M, Rodolfo M, Cavallo F et al. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res 1996; 56:467-70.
11. 11 Chen L, Chen D, Block F., O'Donnell M, Kufe DW, Clinton SK. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 1997; 159:351-9.
12. 12 Lotze MT, Zitvogel L, Campbell R et al. Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann NY Acad Sci 1996; 795:440-54.
13. 13 Atkins MB, Robertson MJ, Gordon MH et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3:409-17.
14. 14 Nastala CL, Edington HD, McKinney TG et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994; 153:1697-706.
15. 15 Zou JP, Yamamoto N, Fujii T et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 1995; 7:1135-45.
16. 16 Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol 1995; 17:71-7.
17. + T cells and granulocyte/ macrophage colony-stimulating factor. J Exp Med 1998; 188:133-43.
18. 18 Cui J, Shin T, Kawano T et al. Requirement for Valphal4 NK T cells in IL-12-mediated rejection of tumors. Science 1997; 278:1623-6.
19. 19 Voest EE, Kenyon BM, O'Reilly MS,Truitt G, d'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87:581-6.
20. 20 Cohen J. IL-12 deaths: explanation and a puzzle. Science 1995; 270:908.
21. 21 Leonard JP, Sherman ML, Fisher GL et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90:2541-8.
22. 22 Sacco S, Heremans H, Echtenacher B et al. Protective effect of a single interleukin-12 (IL-12) predose against the toxicity of subsequent chronic IL-12 in mice: role of cytokines and glucocorticoids. Blood 1997; 90:4473-9.
23. 23 Coughlin CM, Wysocka M, Trinchieri G, Lee WM. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res 1997; 57:2460-7.
24. 24 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-9.
25. 25 Tartour E, Gey A, Sastre-Garau X et al. Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res 1994; 54:6243-8.
26. 26 Tartour E, Gey A, Sastre-Garau X, Lombard Surin I, Mosseri V, Fridman WH. Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst 1998; 90:287-94.
27. 27 Toren A, Barak V, Novick D, Nagler A. Soluble interferon-gamma receptor and interferon-gamma in patients undergoing allogeneic bone marrow transplantation for hematological malignancies. Cytokines Cell Mol Ther 1997; 3:153-8.
28. 28 Leng SX, Elias JA. Interleukin-11 inhibits macrophage interleukin-12 production. J Immunol 1997; 159:2161-8.
29. 29 Bellone G, Aste-Amezaga M, Trinchieri G, Rodeck U. Regulation of NK cell functions by TGF-beta 1. J Immunol 1995; 155:1066-73.
30. 30 Tannenbaum CS, Wicker N, Armstrong D et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 1996; 156:693-9.
31. 31 Morris SC, Madden KB, Adamovicz JJ et al. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J Immunol 1994; 152:1047-56.
32. 32 Bajetta E, Del Vecchio M, Mortarini R et al. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 1998; 4:75-85.
33. 33 Moss ML, Jin SL, Milla ME et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385:733-6.
34. 34 Solomon KA, Covington MB, deCicco CP, Newton RC. The fate of pro-TNF-alpha following inhibition of metalloprotease-dependent processing to soluble TNF-alpha in human monocytes. J Immunol 1997; 159:4524-31.
35. 35 Rivas D, Mozo L, Zamorano J et al. Upregulated expression of IL-4 receptors and increased levels of IL-4 in rheumatoid arthritis patients. J Autoimmun 1995; 8:587-600.
36. 36 Michon JM, Gey A, Moutel S, Tartour E, Meresse V, Fridman W, Teillaud JL. In vivo induction of functional Fc gammaRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). Br J Haematol 1998; 100:550-6.
37. 37 Sgadari C, Farber JM, Angiolillo AL et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997; 89:2635-43.
38. 38 Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87:3877-82.
39. 39 Arenberg DA, Kunkel SL, Polverini PJ et al. Interferon-gamma-inducible protein 10 (TP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996; 184:981-92.
40. 40 Amichay D, Gazzinelli RT, Karupiah G, Moench TR, Sher A, Farber JM. Genes for chemokines MuMig and Crg-2 are induced in protozoan and viral infections in response to IFN-gamma with patterns of tissue expression that suggest nonredundant rales in vivo. J Immunol 1996; 157:4511-20.
41. 41 Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 1985; 315:672-6.
42. 42 Ohmori Y, Hamilton TA. Cell type and stimulus specific regulation of chemokine gene expression. Biochem Biophys Res Commun 1994; 198:590-6.
43. 43 Chilton PM, Fernandez-Botran R. Production of soluble IL-4 receptors by murine spleen cells is regulated by T cell activation and IL-4. J Immunol 1993; 151:5907-17.
44. 44 Blum H, Wolf M, Enssle K, Rollinghoff M, Gessner A. Two distinct stimulus-dependent pathways lead to production of soluble murine interleukin-4 receptor. J Immunol 1996; 157:1846-53.
45. 45 Ruhl S, Pluznik DH, Feldman CM. Soluble interleukin-4 receptor production by murine myeloid progenitor cells: induction by interleukin-6 and interferon-gamma. Cytokine 1993; 5:144-9.
46. 46 Fanslow WC, Clifford KN, Park LS et al. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J Immunol 1991; 147:535-40.
47. 47 Tripp CS, Wolf SF, Unanue ER. Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 1993; 90:3725-9.
48. 48 d'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178:1041-8.
49. 49 Hart PH, Hunt EK, Bonder CS, Watson CJ, Finlay-Jones JJ. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J Immunol 1996; 157:3672-80.
50. 50 Pociot F, Briant L, Jongeneel CV et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23:224-31.
51. 51 Turner D, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24:1-8.
52. 52 Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99:303-10.
53. 53 Wynn TA, Eltoum I, Oswald IP, Cheever AW, Sher A. Endogenous interleukin 12 (IL-12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL-12 both inhibits and prophylactically immunizes against egg pathology. J Exp Med 1994; 179:1551-61.
54. 54 Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263:235-7.
55. 55 Wang ZE, Zheng S, Corry DB et al. Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci USA 1994; 91:12932-6.
56. 56 Finkelman FD, Madden KB, Cheever AW et al. Effects of interleukin 12 on immune responses and host protection in mice infected with intestinal nematode parasites. J Exp Med 1994; 179:1563-72.
57. 57 Tartour E, Fridman WH. Cytokines and cancer. Int Rev Immunol 1998; 16:683-704.
58. 58 Tahara H, Zeh HJ III, Storkus WJ et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54:182-9.
59. 59 Schmidt W, Schweighoffer T, Herbst E et al. Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA 1995; 92:4711-4.
60. 60 Schwartzentruber DJ. In vitro predictors of clinical response in patients receiving interleukin-2 based immunotherapy. Curr Opin Oncol 1993; 5:1055-8.
61. 61 Herrmann F, Helfrich SG, Lindemann A, Schleiermacher E, Huber C, Mertelsmann R. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia. J Clin Oncol 1992; 10:631-4.
62. 62 Tartour E, Blay JY, Dorval T et al. Predictors of clinical response to interleukin 2 based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996; 14:1697-703.